{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 40,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a process flow diagram to illustrate clinical trial dose escalation cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/34",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Group A, B, and C trial flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c43de42-becb-4ff2-9b28-29f8b1fd8a26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.17,
        "y": 0.75
      },
      "kind": "list",
      "text": "DL1A: MABEL based starting dose 0.04 µg/kg; The actual number of dose levels depends on the dose level at which the first Grade ≥2 AE or DLT occurs; MTD: Maximum tolerated dose; PAD: Pharmacologically active dose; Dosing schedule: every week (QW) initially, every two weeks (Q2W) may also be explored; PDL1C: first priming dose level; PDLxC: final priming dose level",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1377383-9903-4990-ae2e-75484a2ccfd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.65,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Part 2: Open-label study to evaluate the efficacy and safety of BA3182 in patients with advanced adenocarcinoma who have a qualifying EpCAM-expressing tumor membrane percent score (TmPS).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f363aec-cf82-4326-bce3-2442abbe1305",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.65,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Part 1: Up to 128 patients with advanced adenocarcinoma. 8 patients in the accelerated titration. 60 in each of the 2-treatment schedules for 10 planned standard titration dose levels.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebd879e8-1ccf-4d15-9a09-7e7788d47bd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1/2 trial design for CAB-EpCAM x CAB-CD3 Bispecific TCE (BA3182)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a86c8c92-4261-43c8-87c7-0e12f5297607",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "9c6f5b16-d8ce-45d2-b83f-f6884e5cd49a",
      "evidence": "Flowchart showing dose escalation steps",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}